Highly Sensitive Solid-Phase lmmunoenzymometric Assay for Placental and Placental-Like Alkaline Phosphatases with a Monoclonal Antibody and Monodisperse Polymer Particles
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We have used a mouse monoclonal antibody (H7) to placental alkaline phosphatase (PLAP, EC 3.1.3.1) in developing an immunoenzymometric assay for PLAP and PLAP-like enzymes. The antibody is bound to sheep anti-mouse IgG (Ab2) covalently coupled to tosylated shell-and-core light (1.07 g/cm3) monodisperse polymer particles. Adding the H7-Ab2-polymer particle suspension to a PLAP-containing sample gives maximal binding of the antigen within 10 mm. PLAP and PLAP-Iike enzymes remain active and bound to the solid-phase throughout all assay manipulations, and can thus be saved for future testing. In testing the enzymes for inhibition by L-Phe, L-Phe-Gly-Gly, L-Leu, and L-homoarginme, the effect of all the inhibitors is fully reversible. The assay is highly versatile, and its sensitivity (routinely 0.05 pg/L) can be increased 1000-told by adjusting the sample volume and incubation time (sample volume is irrelevant between 50 L and 5 mL). We have measured the basal activities of PLAP in men and women and, by using enzyme inhibitors, have characterized it as corresponding to the PLAP-like phenotypes described in normal human testis.
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Human placental alkaline phosphatase (orthophosphoric monoester phosphohydrolase, EC 3.1.3.1, PLAP) is a polymorphic enzyme, expressed in high amounts by the syncytiotrophoblast after the 12th week of pregnancy (1, 2).
Trace activities
of FLAP have also been demonstrated in normal cervix (3, 4) and lung (5) .
PLAP-like enzymes are expressed in trace amounts in normal human testis (5, 6) and thymus (5), and are present in high concentrations in tumor tissue as well as in the serum and fluids of patients with different malignancies, especially seminoma of the testis (7) (8) (9) and ovarian tumors (10) (11) (12) .
PLAP and FLAP-like enzymes can be distinguished by use of carefully cross-absorbed polyclonal antibodies (13), or monoclonal antibodies (14), and by their differential susceptibility to inhibition by hydrophobic amino acids and peptides (15,16). Some investigators have suggested that PLAP and PLAP-like enzymes may result from the expression of two different structural genes (13, 14, 17).
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murine monoclonal antibody (H7) that reacts with an epitope common to the allelic variants of PLAP and the different phenotypes of PLAP-like enzymes. The solid-phase matrix of the assay is monodisperse polymer particles. The assay is fast and simple, is much more sensitive than other currently available methods, and allows quantification of PLAP and PLAP-like enzymes in biological fluids. By using this assay in conjunction with enzyme inhibitors, we have been able to measure and characterize previously undetectable basal concentrations of PLAP-like antigen in sera of healthy individuals.
Materials and Methods

Samples
Serum samples were obtained from healthy blood donors attending the State Serum Institute, Copenhagen, Denmark, and from women in their 15th to 16th week of pregnancy, who were undergoing routine screening for fetal neural tube defects at the State Serum Institute.
Reagents
Antibodies.
The H7 monoclonal antibody was produced as described (14) by fusing spleen cells of BALB/c mice (immunized with purified FS phenotype of PLAP) with X63-Ag8 P635 myeloma cells (19) . The H7 monoclonal antibody is of IgG2a ic subclass, and reacts with the common phenotypes of PLAP as well as with all the phenotypes of testicular PLAPlike enzymes (14) . Sheep anti-mouse IgG were produced and purified as previously described (20) .
Hydrophilic monodisperse particles.
We used monodisperse polymer particles (MPP) of the shell-and-core type prepared by copolynierization of methylmethacrylate, hydroxyethyl methacrylate, and ethylene glycol dimethylacrylate in the presence of particles of methylstyrene-divinylbenzene, 2.9-inn in diameter, according to Ugelstad et al. (21) . The diameter of the final particles was 3.3 tim, the density 1.07 g/cm3, and the surface area 1.7 m2/g. The particles are commercially available as Dynospheres#{174} XP 4101 (Dyno Industrier A/S, Oslo, Norway).
Solid-phase reagent.
Sheep anti-mouse IgG (Ab2) was bound to p-toluenesulfonyl chloride-activated (tosylated) MPP as previously described (22). To bind the H7 monoclonal antibody to the MPP-Ab2, we incubated overnight, with end-over-end rotation, the H7 monoclonal antibody/particle mixture, including trace amounts The reagent was then diluted soas to contain 0.2 g of 117 monoclonal antibody per 100 jL of particle suspension.
Upon centrifugation, the particles 
Results
Assay conditions.
In the present immunoassay for FLAP, the enzymic activity of the antigen is used as the detection step, after specific binding to a solid-phase monoclonal antibody, i.e., MPP-Ab2-H7. As Figure 1 shows, the reaction rate is proportional to the amounts of bound FLAP. The quantity of monoclonal antibody per assay tube (0.2 g) suffices to bind as much as 10 ng of PLAP under the specified assay conditions, i.e., 20-fold the amounts shown in Figure 1 . Because of the unusual heat stability of FLAP, the incubation time can be greatly prolonged without damage to the catalytic activity of the enzyme. Thus by changing incubation time the sensitivity of the assay can be adjusted as needed.
The Michaelis-Menten constants bound to microtiter wells. This difference is most probably ascribable to the very effective interaction between antigen and antibody provided by the homogeneous and stable suspension of these low-density polymer particles, because the amount of antibody and total exposed area are identical in both assays.
Another important advantage of the polymer particles system with respect to microtiter plate systems is exemplified in Figure 3 . When microtiter wells are used, sample volume is usually restricted to 200 tiL. When the MPP suspension is used, sample size can be varied from 50 ,uL up to 5 mL, and uptake of the antigen is linearly related to volume. Thus, by increasing sample size alone, the sensitivity of this IEMA can be increased 100-fold.
Inhibition studies. The H7 monoclonal antibody used in this assay shows very high affinity for PLAP, approximately The experiment depicted in Table 1 was designed to study the reversibility of enzyme inhibition as well as the stability was added to the tubes and incubated for 30 mm to measure activity remaining (and percent inhibition) in the presence of L-homoarginine, L-Fhe, L-Phe-Gly-Gly, and i,.Leu (cycle 2). After washing, substrate was once again added to all tubes to measure the total activity that could be accounted for upon "washing away" the inhibitor (cycle 3). Thereafter, each substrate-inhibitor solution was tested on each set of B tubes with alternating washing and total-activity determi-N nations (cycle 4-9). The set of tubes labeled 6 was not exposed to buffered substrate solutions until the last cycle.
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The activity of this "virgin" set was identical to the activities of the sets subjected to the eight previous cycles, indicating the complete stability and analytical recovery of the bound PLAP activity. These experiments indicate that (a) the inhibition of PLAP by the different amino acids and peptides is reversible, because full enzymic activity is accounted for after "washing away" the inhibitor, Absolute frequency a Eachofthree tubes per setcontained5 ngof PLAP bound toMPP-Ab2-H7 andwasassayedfortotalalkaline phosphatase activityIn cycles 13, 5, 7, and 9. In ycles 2,4, 6, and 8, each set was assayedfor total activity (T) or activity remaininginthe presenceof L-Phe(P), L-Phe-GIy-GIy(PGG),L-Leu(L),or L-homoarginlne H).Theactivity of eachsetwascompared with the activity of set I in each cycle. All tubes werewashed betweencycles as described in Materialsand Methods. Table 2 , all serum samples from normal men and women contained a FLAP-like antigun that displays catalytic properties identical to the PLAPlike enzyme found in trace amounts in normal human testis. Equivalent amounts of MPP-Ab2-H7-bound FLAP from the sera of pregnant women between the 15th and 16th weeks of gestation showed a clearly different pattern of inhibition, which was, in turn, identical to the pattern displayed by the standard PLAP preparation.
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DiscUssion
The enzyme-antigen immunoassay principle, in which the enzymic activity of FLAP is measured at the detection step, has been described previously (27, 28) . The principle has been used to screen for positive hybridoma cultures secreting anti-PLAP monoclonal antibodies. An enzyme ixnmunoassay involving the H317 monoclonal antibody (29) has been used to measure PLAP concentrations in serum throughout pregnancy. Five monoclonal antibodies (F11, D10, C2, H7, and B10) to PLAP-allelic variants have previously been developed and characterized (14). The antibodies react with epitopes mapped on two different antigenic domains on the molecule, and they detect structural differences between PLAP-allelic variants and normal (and tumor-derived) FLAP-like enzymes. One Of these antibodies (H7) reacts with an epitope common to all forms of FLAP This sheep anti-mouse spacer ann places the H7 antibody in a very favorable orientation. In our experience, direct coupling of the antibody of interest to solid-phase particles results in a considerable loss of binding capacity. The monodisperse polymer particles we used here have a density approximating that of normal human serum. Therefore continuous mixing or end-over-end rotation is not necessary, even when large volumes of PLAP-containing samples are being incubated, because the particles will remain in a homogeneous suspension throughout the incubation (up to 24 h). This homogeneous suspension of the particles in the sample fluid provides very effective surface contact of the antibody with the antigen population. Effectiveness of binding is greatly increased as compared with the more commonly used microtiter wells as solid-phase matrix, where the antigen has to difli.ise toward the antibodies coating the wells. Binding of the antigen to the MPPAb2-H7 reagent is complete within 10 mm; in contrast, 24 h is required for complete binding by the H7 antibody bound to microtiter wells. Thus assay time is considerably shortened. The H7 monoclonal antibody shows very high affinity for FLAP and PLAP-like enzymes. After binding is accomplished, the association is completely stable throughout all assay manipulations. In practice this implies that precious sample material (i.e., tumor enzymes from biological fluids) can be assayed and "stored" bound to the particles. The particles can subsequently be split and assayed for the enzyme susceptibility to different amino acids (as in the present paper) or can be probed for structural differences by using monoclonal antibodies labeled with horseradish peroxidase or 1I in assays equivalent to the "sandwich" enzyme immunoassay and immunoradiometric assay described elsewhere (14, 18).
Previously, with the polyclonal sandwich enzyme immunoassay (26), the upper normal limits of basal FLAP serum concentrations could be measured in a reference population, but 70% of the population had FLAP concentrations that were undetectable by that assay (0.4 ,u.gtLsensitivity limit). With the present assay we could easily measure the whole distribution of normal values in a healthy reference population and, in turn, were able to characterize the antigen as corresponding to a FLAP-like enzyme by use of enzyme inhibitors. We don't know which tissue is contributing this normal basal level of FLAP-like enzyme. FLAP-like antigens have been described in normal human testis, thymus, and endometrium-any of these tissues could be responsible. A recently described immunoassay involving the H317 monoclonal antibody (29) has not detected any measurable FLAP-like enzymes in normal human testis and in normal serum, probably because of the more restricted specificity of the H317 antibody, which recognizes neither the FF-allelic variant of FLAP nor the testicular , personal communication, 1984) . Thus, in this respect, the H317 antibody resembles the previously described F11 and C2 monoclonal antibodies (14). The present assay based on the H7 monoclonal antibody is valid for the quantification of both PLAP and PLAP-like enzymes. This specificity is essential if one is to follow values for PLAP and PLAP-like enzymes as a marker of malignant disease. Our preliminary results in the follow-up of patients with different ovarian tumors indicate that both FLAP and PLAP-like enzymes might be expressed in certain tumor patients, and even that both types of enzymes can be expressed by the same tumor, either concomitantly or sequentially, as a result of treatment.
PLAP-like enzymes (McLaughlin and Johnson
